Özet:

OBJECTIVE: Advanced lung cancer inflammation index (ALI) is one of the recently evaluated inflammatory indexes in many cancers, foremost Non-Small Cell Lung Cancer (NSCLC). However data in the same issue in Small Cell Lung Cancer (SCLC) cases is scarce. In this study the its aimed to investigate the correlation between pretreatment ALI and survival in limited stage SCLC patients treated with curative intend. MATERIAL AND METHODS: Twenty-one limited stage SCLC patients who underwent definitive thoracic radiotherapy (RT) were retrospectively evaluated. RT was given as median 60 Gy using 3D conformal (3DCRT) or intensity modulated RT (IMRT) techniques. Variables used to calculate ALI value were attained from the electronical charts of the patients. Patients were evaluated in two groups as low and high ALI value. Kaplan Meier survival analysis was used to achieve overall (OS) and progression free survival (PFS) results for both groups. Univariate and multivariate analysis were done by Cox regression test. RESULTS: Five patients are alive after median 26 (5,16-70,6) months of follow up. Local and distant recurrence rates were found to be 47,6% and 57,1% respectively. PFS and OS of whole cohort were median 13,7 (5,16-82,76) and 25,07 (6,9-85,59) months respectively. Median OS and PFS of group with ALI<38 were 22,4 and 13,56 months where in the group with ALI >38, they were 25,06 and 13,7 respectively (p=0,709 ve p=0,744). None of the other variables investigated in uni and multivariant analysis were found to be statistically significant (p=0,059-0,930 for univariant analysis and p=0.07– 0.89 for mutivariant analysis). CONCLUSIONS: In our study we detected that pretreatment ALI value have no prognostic effect on survival in limited stage SCLC cases. The discordance between our results and the previous reports can be attributed to high ALI values in our series compared to previous studies and enrolment of only limited stage SCLC patients.

Anahtar Kelimeler: